DFP-17729

DFP-17729 is an oral small molecule anticancer agent developed by Delta-Fly Pharma. It is classified as both an alkalinising agent and an antineoplastic. The drug’s primary mechanism involves neutralizing the acidic microenvironment surrounding cancer cells, which is believed to contribute to tumor progression and resistance to therapy. By alkalinizing this environment, DFP-17729 aims to inhibit cancer cell survival and enhance therapeutic efficacy. The drug has been studied in combination with TS-1 (an oral fluoropyrimidine) for the treatment of refractory or late-stage pancreatic cancer, particularly after third-line treatment failure. Clinical data suggest that urinary alkalinization correlates with improved median overall survival in this patient population[1][5][6][7].